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[974-85[ The Red~~tioninRate~f Peri-angiopla~W
Myocardial Infarction Aftar Traatmant with llb/llla
Receptor Antagonists is Dependent on Ml
Definition
W.D. Weaver, A.M. Ross, S.J. Yakubov, L.1.Dackelbaum, J. Midwall. Henry
Ford Hospital, Detroit Ml, USA
The effectiveness of GP llb/llla receptor antagonists is often assessed using
a eompoaite endpoint of death, myocardial infarction (Ml), and urgent revas-
cularizstion. Blinded committees have usad clinical events (chest pain and
ECG changes), and quantitative unstandardized enzyme criteria (often
clinically silent) to determine Ml.
RESTORE was a 2,139 pt comparison of tirofiban vs placebo in “high
risk” angioplasty. The definition for Ml was clinical (pain, ECG and enzymee)
or CK-MB elevation (23x nl in hospital or 2x nl from discharge to 30 days).
There was a 26% reduction (p= 0.113) in Ml in the tirofiban group. If higher
anzyme levels had been used, the effect of tirofiban increased: CK-MB z 3X
elevated = 36Y0 reduction (p = 0.04); ?4x elevated = 39% (p = 0.04); 24x
elevated = 397. (p = 0.04); 25x elevated = 41Y0(p = 0.04); ?IOX elevated
= 56% (p = 0.019). Uaing the investigator clinical diagnosis, Ml reduction
wee 27% (p= 0.246). Each of these alternative Ml definitions also influenced
the composite primaty endpoint: 16% reduction using protocol definition (p
= 0.16); 19% using CK-MB 23x (p = 0.093); and 20% using investigator
diagnosis of Ml (p = 0.074).
These findinga suggest that the outcome of GP llb/Hla trials having Ml
as an endpoint can be markedly influenced by the enzyme criteria for ML
The clinical outcome associated with the enzyme levels needs definition so
a meaningful standard can be adopted.
a97486 Ticlopidine Potentates Abciximab’a Ability toInhibit ADP-induced Plateiet Aggravation In Vitro
N.S. Kleiman, M.A. Mascelli, N. Graziadei, K. Maresh, A. Edwards,
L. Baysinger, A. Fischer, E. Lance, C. Cabot, R. Jordan. /3ay/orCollege of
Medicine; Centow Inc. Houston Tx., USA, Bayior College of Medicine;
Centocw Inc. Maivem Pa., USA
Abeiximab (7E3) is indicated in pts undergoing high risk PTCA. Increasingly
such pts raceiva intracoronary etents and are also treated with theantiplatelat
drug ticlopidine (T) which depresses platelet function by inhibiting ADP-
mediatad aggregation. The combined interaction between these agents is
unknown. We studied this interaction in vitro in 10 pta receiving aspirin and
T (500 mg immediately after stenting and continued at 250 mg BID) and in 3
pts treated with aspirin only after PTCA. At baseline, concentrations of ADP
producing the maximal aggregation response for each individual patient
were determined in citrate-anticoagulated platelet-rich plasma (range 5-6
vM). Using these agonist concentrations, IC50Sfor axoganously added 7E3
were determined at baseline, 16-36 hours, and 7-10 daye. IC50S(@mL)
of 7E3 ware:
the mAb 7A1O (specific for a Mac-1 activation neoepitopa) demonstrates
similar binding of c7E3 on activated and nonactivatad Mac-1. Flow cytometry
with a chicken anti-fibrinogen mAb reveals inhibition of fibrinogen binding on
Mac-1 by c7E3 (half maximal: 2, maximal: 10 @/ml c’7E3).Aggregation of
the PMA-stimulated human monocytic ceil line U937 is totally blocked with
10 @ml of c7E3. Cell adhesion of U937 on fibrinogen is blocked by 77 ~ 5
percent (P < 0.002) with 10 r.@/mlof c7E3.
Conclusions: c7E3 binds to the activated and nonactivatad Mac-1 with
similar affinity. Thus, fibrinogen binding to Mac-1, and Mac-l-mediated cell
adhesion and aggregation are effecfivaly inhibitad by therapeutic conoantra-
tions of c7E3. The blockade of Mac-1 may contribute to the short term but
evan more to the long-term clinical benefits of c7E3.
D97488 Platelet Aggregationsnd Fibrinogen Binding inPatiants Treated with intarmelinand Abciximab
During Coronary Angiopl;aty
C.R. Wells, P.J.Goldschmidt, L.D. Coleman, V.J. Coombs, G. Geretenblith,
J.A. Brinker,J.R. Reear. Johns Hopkins /-/ospita/,Ba/?imore,MD, USA
Inhibition of platelet aggregation (PA) by glycoprotein (GP) llb/Hla receptor
antagonists reduces abrupt closure and myocardial infarction after coronary
angioplasty (PTCA). We compared the effects of Integrelin and Abciximab
on ADP-stimulated (20 Mm) PA and on fibrinogen binding to activated GP
llb/llla receptors using fluorescein isothiocyanate fibrinogen (FITC-FGN).
We studied 13 controls, 25 IMPACT-IIpatients treated with Integrelin, and 14
patienta treated with Abciximab during PTCA. Integrelin dosing was based on
in vitroassaysof Integrelin-induead inhibition of PA,which we have previously
shown is potentiated when citrate-containing samples are used. PA and
FITC-FGN binding did not differ among the three groups at baseline and did
not change in the control group following PTCA. There was no statistical.
difference in the inhibition of PAbetween Integrelin and Abciximab. However,
inhibition of FITC-FGN binding was significantly greater with Abciximab than
Integrelin (76 vs 42%, p = 0.026).
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This difference may be due to underdosing of Integrelin in the IMPACT-II
study or to inherent differences in the two agent’s binding and/or affinity for
the GP llb/llla receptor.
Baseline 1S-36 H 7-10 D
1.08 + 0.26 0.98 + 0.2 0.70+ 0.13
P(3aaaline-18-36 H) = 0.12; P (Baseline- 7-10 D) <0.003
In pte reeeiving aspirin alone, there were no differences between either
time point and baseline.
These findings indicate a subtle interaction between in vivo T and abcix-
imab’s ability to inhibit ADP-inducad platelet aggregation after the first waek
of traatment but not the first day. Clinical evaluations in pts treated with both
agents will define the combined pharmacodynamic effects of both abciximab
and ticlopidine.
D97467 The Antibody Fragment c7E3 (ReoPro@)Binds to
Activated and Nonactivated Mac-1 on Granule- and
Monocytes and Blocks Mac-l-mediated Cell
Adhaaion and Aggregation
K. Peter, M. Schwam, P. Majer, B. Kohler, T. Nordt, C. Bode. Internal
Medicine Ill, University of Heidelberg, Heidelberg, Germany
The humanized Fab fragment c7E3 binds to the platelet integrin GPllb/llla
end thereby blocks fibrinogen binding to platelets, The clinical benefits of
c7E3 are mainly attributed to the inhibition of platelet aggregation and ad-
hesion. Since fibrinogen is not only a Iigand for GPllb/llla but also for the
leukocyte integrin Mac-1, we evaluated whether c7E3 is able to block Mac-1
(CD llb/CD 18) with similar characterktics as c7E3 blocks GPllb/llla.
The binding of c7E3 and fibrinogen to Mac-1 was evaluated with flow
cytometry of whole bltmd samples. c7E3 binds to resting granule- and mono-
eytes (half maximal: 1, maximal: 10 #@ml). This binding can be inhibited by
monoclinal antibody (mAb) 44 (anti-CDllb, 10 ug/ml). A comparison with
1974-891f.fseOfAbciximab (ReOprO@)isNOtAssociated
With an Increase in the Riak of Stroke: Ovarview of
Thraa Randomized Triais
J. Deckers, R.M. Califf, E.J. Topol, A.M. Lincoff, J.E. Tcheng, M.L. Simoons.
Thoraxcentec Rotterdam, The Nethedands, Duke Clinical Research
/nstitute, Durham, NC, USA
Abciximab (ReoPro) isa potent glycoprotein llb/llla receptor antagonist used
to prevent ischemic complications of percutaneous intervention. Because of
its antithrombotic effect, concern exists about the effect of abciximab on the
risk of stroke. Three large randomized clinical trials have randomly allocated
patients to treatment with abciximab. All trials used concomitant heparin,
although the dose in EPIC and CAPTURE was higher than tha dose in
EPILOG. The duration of the infusion varied, but all trials used a bolus of
0.25 mg/kg of abciximab followed by an infusion of 0.10 #g/min. The number
of strokes in each trial are shown.
EPIC CAPTURE EPILOG TOTAL
D A P A Pd P A
N 681 678 630 623 914 1811 2225 3112
Non-hem 2 2 2 0 0 2 4 3
Hem 2 2 1 0 0 4 3 6
Unk o 0 0 1 0 0 0 1
Anv 4 4 3 1 0 6 7 10
All pvalues >0.45: P = placebo, A = abcix!mab, Nomhem = non-hemorrhagic atroke, Hem
= hemorrhagic stroke, Unk = unknown atiology.
When used according to protocol, there is no evidence of a clinically
meaningful increase in stroke rate with the use of abcixlmab (0.310. with
placeba and 0.35% with abciximab).
